Anteris Technologies gets Medtronic investment

Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company.

Rhea-AI Filing Summary

Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company. The investment is structured under a stock purchase agreement dated January 20, 2026 between Anteris and the Medtronic subsidiary.

On January 22, 2026, Anteris and Medtronic issued a joint press release about this transaction, which is furnished as Exhibit 99.1. The disclosure is provided under Regulation FD, meaning it is intended to share the same information with all market participants at the same time.

Insights

Equity analyst – medical technology partnerships

Medtronic’s strategic investment signals a notable relationship for Anteris, but specific financial impact is not detailed here.

The disclosure shows that Anteris Technologies Global Corp. entered a stock purchase agreement on January 20, 2026 with a wholly owned subsidiary of Medtronic plc. Describing the transaction as a “strategic investment” suggests a relationship that goes beyond a purely financial holding, although the excerpt focuses on the fact of the investment, not its size or terms.

The joint press release dated January 22, 2026 is furnished under Regulation FD, indicating an effort to provide equal access to this information for all investors. Future company communications and periodic reports will be the place where any operational or financial consequences of this Medtronic relationship are described in more detail.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anteris Technologies Global Corp. (AVR) announce with Medtronic?

Anteris Technologies Global Corp. announced that Medtronic plc, through a wholly owned subsidiary, is making a strategic investment in the company under a stock purchase agreement dated January 20, 2026.

How is the Medtronic investment in Anteris (AVR) being documented?

The investment is documented in a stock purchase agreement dated January 20, 2026 between Anteris Technologies Global Corp. and a wholly owned subsidiary of Medtronic plc.

What is included in Exhibit 99.1 of Anteris Technologies Global Corp.’s 8-K?

Exhibit 99.1 contains the joint press release issued by Anteris Technologies Global Corp. and Medtronic plc on January 22, 2026 announcing Medtronic’s strategic investment.

Under which SEC item did Anteris Technologies Global Corp. (AVR) disclose the Medtronic investment?

Anteris Technologies Global Corp. disclosed the Medtronic strategic investment under Item 7.01, Regulation FD Disclosure.

Is the Medtronic strategic investment information considered filed or furnished by Anteris (AVR)?

The information about the Medtronic strategic investment, including the joint press release, is being furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act.

When was the joint press release about the Medtronic investment in Anteris (AVR) issued?

The joint press release announcing Medtronic’s strategic investment in Anteris Technologies Global Corp. was issued on January 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/22/2026 - 05:18 PM Learn about SEC filing dates

false000201151400020115142026-01-222026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2026

Anteris Technologies Global Corp.

(Exact name of registrant as specified in its charter)

Delaware	001-42437	99-1407174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD Australia	4066
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: +61 7 3152 3200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AVR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD Disclosure.

On January 22, 2026, Anteris Technologies Global Corp. (the “Company”) and Medtronic plc (“Medtronic”) issued a joint press release announcing a strategic investment from Medtronic plc (through a wholly owned subsidiary) in the Company, pursuant to a stock purchase agreement, dated January 20, 2026, by and between the Company and a wholly owned subsidiary of Medtronic. A copy of the joint press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed with this Current Report on Form 8-K:

Exhibit No.		Description
99.1		Press Release, dated January 22, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Anteris Technologies Global Corp.
Date: January 22, 2026
	By:	/s/ Wayne Paterson
	Name:	Wayne Paterson
	Title:	Vice Chairman and Chief Executive Officer